The Diagnostic Problem
Despite advances in surgery and chemotherapy, survival outcomes for osteosarcoma have changed little in more than 30 years – largely because metastasis is detected too late.
Current diagnostics rely on imaging (often after spread has occurred), tumor grading based on appearance, and limited ability to predict which patients will relapse.
That gap is what researchers at the Ontario Veterinary College (OVC) are working to close.
DOGBONe: A Comparative Oncology Breakthrough
The Dog Osteosarcoma Group – Biomarkers of Neoplasia (DOGBONe) is an interdisciplinary initiative studying naturally occurring osteosarcoma in pet dogs to identify molecular signals that predict disease progression.
Researchers discovered that specific microRNAs – small molecules that regulate gene expression – are elevated in dogs with aggressive osteosarcoma and correlate with faster disease spread and shorter survival times
MicroRNAs are present throughout the bloodstream, making them attractive candidates for minimally invasive blood tests.
Why microRNAs Matter
MicroRNAs are increasingly recognized as powerful disease indicators. Their significance was underscored when U.S. scientists were awarded the 2024 Nobel Prize in Medicine for discoveries related to their role in biology.
In cancer, abnormal microRNA levels can reveal early metastasis, tumor aggressiveness, and likely treatment response.
DOGBONe’s work suggests these same signals can be leveraged in both dogs and humans.
From Veterinary Discovery to Human Diagnostics
The research team is now translating canine findings into human applications, including development of a lab-on-a-chip diagnostic platform capable of detecting key microRNAs from a small blood sample.
Such a system could detect metastasis earlier than imaging, guide treatment decisions, and reduce unnecessary or ineffective therapies.
Importantly, dogs provide a faster, ethically sound path to validating these tools in real disease conditions.
Impact on Veterinary Patients
For veterinarians and pet owners, earlier and more accurate prognostic tools mean better-informed treatment decisions, clearer expectations about outcomes, and improved quality-of-life planning when cure is unlikely.
This is precision medicine applied responsibly.
Regulatory and Quality Perspective (MDP Insight)
Diagnostic innovation brings its own challenges, including biomarker validation, analytical performance and reproducibility, clinical relevance across populations, and clear claims and labeling boundaries.
Technologies that originate in veterinary medicine but aim for human use must be developed with regulatory convergence in mind from the outset.
A Shared Future for Human and Animal Health
DOGBONe’s work exemplifies a growing truth in modern medicine: advances in animal health and human health are increasingly inseparable.
Studying cancer where it naturally occurs – and where it occurs more frequently – researchers are building tools that may finally change outcomes for one of oncology’s most stubborn diseases.
Read more about DOGBONe.